Literature DB >> 11044478

The renal hemodynamic effects of ibuprofen in the newborn rabbit.

N S Chamaa1, D Mosig, A Drukker, J P Guignard.   

Abstract

In early childhood, nonsteroidal anti-inflammatory drugs are mainly used to either prevent or treat premature labor of the mother and patent ductus arteriosus of the newborn infant. The most frequently used prostaglandin-synthesis inhibitor is indomethacin. Fetuses exposed to indomethacin in utero have been born with renal developmental defects, and in both the unborn child and the term and premature newborn this drug may compromise renal glomerular function. The latter has in the past also been observed when i.v. indomethacin or i.v. acetylsalicylic acid (aspirin) were administered to newborn rabbits. The present experiments were designed to evaluate whether ibuprofen has less renal side effects than indomethacin, as claimed. Three groups of anesthetized, ventilated, normoxemic neonatal rabbits were infused with increasing doses of ibuprofen (0.02, 0.2, 2.0 mg/kg body weight) and the following renal parameters were measured: urine volume, urinary sodium excretion, GFR, and renal plasma flow. Renal blood flow, filtration fraction, and the renal vascular resistance were calculated according to standard formulae. Intravenous ibuprofen caused a dose-dependent, significant reduction in urine volume, GFR, and renal blood flow with a fall in filtration fraction in the animals receiving the highest dose of ibuprofen (2 mg/kg body weight). There was a very steep rise in renal vascular resistance. Urinary sodium excretion decreased. These experiments in neonatal rabbits clearly show that acute i.v. doses of ibuprofen also have significant renal hemodynamic and functional side effects, not less than seen previously with indomethacin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044478     DOI: 10.1203/00006450-200011000-00008

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  9 in total

1.  The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age.

Authors:  Karel Allegaert; Veerle Cossey; Anne Debeer; Jean Paul Langhendries; Bart Van Overmeire; Jan de Hoon; Hugo Devlieger
Journal:  Pediatr Nephrol       Date:  2005-03-23       Impact factor: 3.714

2.  The renal adverse effects of ibuprofen are not mediated by AQP2 water channels.

Authors:  Rachel Vieux; Marina Zelenina; Anita Aperia; Jean-Michel Hascoët
Journal:  Pediatr Nephrol       Date:  2010-07       Impact factor: 3.714

Review 3.  Ontogeny of drug elimination by the human kidney.

Authors:  Nancy Chen; Katarina Aleksa; Cindy Woodland; Michael Rieder; Gideon Koren
Journal:  Pediatr Nephrol       Date:  2005-12-06       Impact factor: 3.714

4.  Ibuprofen-related renal tubular acidosis in pregnancy.

Authors:  Andrew Mallett; Matthew Lynch; George T John; Helen Healy; Karin Lust
Journal:  Obstet Med       Date:  2011-08-23

Review 5.  Nonsteroidal anti-inflammatory agents in neonates.

Authors:  John L Morris; David A Rosen; Kathleen R Rosen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  The adverse renal effects of prostaglandin-synthesis inhibition in the fetus and the newborn.

Authors:  Alfred Drukker
Journal:  Paediatr Child Health       Date:  2002-10       Impact factor: 2.253

Review 7.  Comparative tolerability of pharmacological treatments for patent ductus arteriosus.

Authors:  C Hammerman; M Kaplan
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

8.  Cyclooxygenase (COX) Inhibitors and the Newborn Kidney.

Authors:  Francine G Smith; Andrew W Wade; Megan L Lewis; Wei Qi
Journal:  Pharmaceuticals (Basel)       Date:  2012-10-25

9.  Mechanochemical prepared ibuprofen-Polygonatum sibiricum polysaccharide drug delivery system for enhanced bioactivity with reduced renal injury induced by NSAIDs.

Authors:  Wenhao Xu; Jinli Yang; Xiangyang Gu; Wenjing Su; Faxiang Pu; Zhangfu Xie; Kongliang Jin; Weike Su; Lichan Mao
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.